PLANO, Texas, Feb. 29, 2016 -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute Dallas Texas – to work on key elements of its new high-purity lead-212 (212Pb) production facility under construction in Plano, Texas.
|
||||||
Five teams composed of 35 students from both schools will work on design proposals for the lobby, conference room, and “monument sign” in front of the building. AREVA Med will assess the projects and select the best design for this state-of-the-art facility. The winning team will see the results of their project at the opening ceremony.
Patrick Bourdet, CEO of AREVA Med said: “This project is symbolic of AREVA Med’s innovative and collaborative spirit and, demonstrates our commitment to the local community and our willingness to facilitate exchanges between people from different cultures. This is also an excellent way for students to work on a real project and see the tangible results of their accomplishments.”
Heather Carter, Interior Design Program Coordinator at the Art Institute of Dallas, said: “Understanding global perspectives is one of the professional standards our students must meet as part of our interior design program. This collaboration with French peers will give our students an opportunity to develop their knowledge of another culture and they are excited to work with other programs and nations in blended teams. It is a very positive undertaking, and we appreciate AREVA Med for initiating it.”
Séverine Nomdedeu, Director of École Supérieure de Design Troyes, added: “Managing practical projects is at the heart of our strategy. Made possible by AREVA Med, the collaboration with the Art Institute of Dallas represents a tremendous opportunity to exchange, share, and create, and is in line with the transcultural opening that we hope to bring to our students and the way we teach design.”
More information at www.arevamed.com, http://www.groupe-esc-troyes.com/, and https://www.artinstitutes.edu/dallas/Programs/Interior-Design/447
More about AREVA Med
AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new therapies to fight cancer. AREVA Med has developed a unique process to extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells. AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform. For more information: www.arevamed.com. Follow @AREVAmed on Twitter.
Press Contacts AREVA Med Alison Tise (301) 841-1673 [email protected] @AREVAmed


MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
OpenAI Explores Massive Funding Round at $750 Billion Valuation
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 



